PublicationsSee our latest research publications SOL578, Poster James Cotton 25/01/2023 SOL578, Poster James Cotton 25/01/2023 PEP07: A novel, brain penetrant oral Chk1 inhibitor for the treatment of AML and MCL Read More SOL784, Poster James Cotton 13/09/2021 SOL784, Poster James Cotton 13/09/2021 S6K1 inhibitors for fragile X syndrome and triple negative breast cancer Read More SOL578, Poster James Cotton 01/07/2017 SOL578, Poster James Cotton 01/07/2017 Preclinical pharmacokinetics of CASC-578, a novel, selective, potent, and orally bioavailable small molecule checkpoint kinase 1 inhibitor Read More SOL578, Poster James Cotton 01/07/2017 SOL578, Poster James Cotton 01/07/2017 The novel orally available sub-nanomolar potent and selective checkpoint kinase 1 inhibitor CASC-578 is highly active in mantle cell lymphoma as a single agent and in combination with Wee1 inhibition Read More SOL578, Poster James Cotton 01/07/2017 SOL578, Poster James Cotton 01/07/2017 CASC-578, a novel Chk1 inhibitor, is active as a single agent in solid tumors and displays synergistic anti-tumor activity in combination with Wee1 inhibition Read More SOL784, Poster James Cotton 29/11/2016 SOL784, Poster James Cotton 29/11/2016 Preclinical validation of a novel compound targeting p70S6 Kinase in breast cancer Read More Discover our cutting-edge scientific pipeline for cancer therapies Learn more
SOL578, Poster James Cotton 25/01/2023 SOL578, Poster James Cotton 25/01/2023 PEP07: A novel, brain penetrant oral Chk1 inhibitor for the treatment of AML and MCL Read More
SOL784, Poster James Cotton 13/09/2021 SOL784, Poster James Cotton 13/09/2021 S6K1 inhibitors for fragile X syndrome and triple negative breast cancer Read More
SOL578, Poster James Cotton 01/07/2017 SOL578, Poster James Cotton 01/07/2017 Preclinical pharmacokinetics of CASC-578, a novel, selective, potent, and orally bioavailable small molecule checkpoint kinase 1 inhibitor Read More
SOL578, Poster James Cotton 01/07/2017 SOL578, Poster James Cotton 01/07/2017 The novel orally available sub-nanomolar potent and selective checkpoint kinase 1 inhibitor CASC-578 is highly active in mantle cell lymphoma as a single agent and in combination with Wee1 inhibition Read More
SOL578, Poster James Cotton 01/07/2017 SOL578, Poster James Cotton 01/07/2017 CASC-578, a novel Chk1 inhibitor, is active as a single agent in solid tumors and displays synergistic anti-tumor activity in combination with Wee1 inhibition Read More
SOL784, Poster James Cotton 29/11/2016 SOL784, Poster James Cotton 29/11/2016 Preclinical validation of a novel compound targeting p70S6 Kinase in breast cancer Read More
